Aytu BioPharma, a Denver-based pharmaceutical company focused on central nervous system disorders, reported $16.1 million in revenue for the fourth quarter of fiscal 2026, representing a 6.4% increase from $15.1 million during the corresponding quarter a year earlier. The results were supported by the commercial launch of EXXUA, which generated $3.9 million in quarterly revenue, while total prescriptions for the antidepressant increased approximately 138% from the preceding quarter.
For the quarter ended June 30, 2026, Aytu reported $0.5 million in adjusted EBITDA, compared with $2 million during the prior-year period.
The company reported a net loss of less than $100,000, compared with a net loss of approximately $19.8 million during the fourth quarter of fiscal 2025.
The latest quarterly results included a $1 million gain related to derivative warrant liabilities, while the previous year’s fourth quarter included approximately $18.1 million in combined impairment expenses and derivative warrant liability losses.
The company’s latest results reflect its transition toward commercializing EXXUA, an oral prescription medicine approved for the treatment of major depressive disorder in adults.
EXXUA became commercially available in December 2025, followed by a more formal launch in January 2026 and full sales force deployment in late February.
The fourth quarter of fiscal 2026 represented the product’s first full quarter following its commercial launch.
EXXUA generated $3.9 million in quarterly net revenue, compared with $2.4 million during the preceding quarter.
Total prescriptions increased to 3,323 from 1,398 in the third quarter, representing sequential growth of approximately 138%.
Prescription volume increased throughout the quarter, reaching a monthly record of 1,261 prescriptions in June.
Shipments increased nearly 40% sequentially to approximately 4,600 units, including 2,377 units during June.
According to Aytu, EXXUA adoption has expanded across additional prescribers, geographic markets, and sales territories. The company also reported growing refill activity and continued conversion of patients from initial titration packs to full prescriptions.
These developments have been supported by national physician education programs and expanded commercial activities.
While EXXUA contributed to fourth-quarter revenue growth, Aytu’s established pharmaceutical portfolios continued facing pressure from generic competition and reduced promotional investment.
Its ADHD Portfolio generated $10.4 million in fourth-quarter revenue, compared with $13.1 million during the corresponding period in fiscal 2025.
However, the portfolio improved sequentially from $9.1 million in the third quarter, supported by higher unit sales, improved gross-to-net economics, and relatively stable demand across its established brands.
The Pediatric Portfolio generated $1.8 million in quarterly revenue, compared with $2 million a year earlier. Revenue increased sequentially from $900,000 in the third quarter as product availability normalized following an earlier supply disruption.
Aytu reported fourth-quarter gross profit of $10.4 million, representing approximately 64.6% of net revenue, compared with $10.3 million and a gross margin of 67.8% a year earlier.
The company’s operating expenses increased as it invested in EXXUA’s commercial launch, including spending on its sales force, marketing, promotional materials, and physician engagement.
For the full fiscal year ended June 30, 2026, Aytu reported $57.6 million in net revenue, a decrease of 13.3% from $66.4 million during fiscal 2025.
EXXUA generated $6.6 million in full-year revenue, reflecting the product’s initial commercialization period.
The ADHD Portfolio contributed $45.8 million, compared with $57.6 million during fiscal 2025, while the Pediatric Portfolio generated $5.1 million, compared with $8.8 million a year earlier.
Aytu reported a full-year net loss of $14.3 million, compared with $13.6 million during fiscal 2025.
Full-year adjusted EBITDA was negative $3.7 million, compared with positive adjusted EBITDA of $9.2 million a year earlier, reflecting planned investments in commercializing EXXUA.
The company ended fiscal 2026 with $26.3 million in cash and cash equivalents.
Looking ahead, Aytu plans to continue expanding EXXUA’s commercial presence while managing expenses across its established product portfolio.
Management said it intends to build toward more consistent positive adjusted EBITDA as fiscal 2027 progresses, supported by further EXXUA sales growth and cash contributions from the company’s ADHD and Pediatric businesses.
KEY QUOTE:
“Although we remain in the early stages of the EXXUA launch, the continued momentum we saw throughout the fourth quarter further reinforces our confidence in this exciting opportunity. EXXUA generated $3.9 million in net revenue during the quarter, up from $2.4 million in the third quarter, while more than 3,300 prescriptions were written, more than double the prior quarter.”
Josh Disbrow, CEO Of Aytu BioPharma
